Hemasphere. 2022 Aug 2;6(8):e758. doi: 10.1097/HS9.0000000000000758. eCollection 2022 Aug.
NO ABSTRACT
PMID:35935609 | PMC:PMC9348860 | DOI:10.1097/HS9.0000000000000758
Recent Content
- Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study
- Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse
- A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
- Protocol for cytoskeleton staining of the semi-adherent multiple myeloma cell line RPMI 8226 by immunofluorescence
- Value of third-generation of VNCa dual-energy CT for differentiating diffuse marrow infiltration of multiple myeloma from red bone marrow
- Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
- Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma
- NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma
- Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China
- From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma